Captrust Financial Advisors Neurocrine Biosciences Inc Transaction History

Captrust Financial Advisors

$43.1 Billion
Q2 2025

A detailed history of Captrust Financial Advisors transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Captrust Financial Advisors holds 12,176 shares of NBIX stock, worth $1.76 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,176

Previous 7,310 66.57%

Holding current value

$1.76 Million

Previous $808,000 89.36%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$87.54 - $128.18 $425,969 - $623,723	4,866 Added 66.57%	12,176 $1.53 Million
Q1 2025 May 14, 2025	SELL	$107.22 - $153.29 $464,691 - $664,358	-4,334 Reduced 37.22%	7,310 $808,000
Q4 2024 Feb 14, 2025	BUY	$111.62 - $139.44 $204,934 - $256,011	1,836 Added 18.72%	11,644 $1.59 Million
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $5,958 - $7,963	52 Added 0.53%	9,808 $1.13 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $209,114 - $228,817	1,598 Added 19.59%	9,756 $1.34 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $478,959 - $527,957	-3,673 Reduced 31.05%	8,158 $1.13 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $886,214 - $1.11 Million	8,355 Added 240.36%	11,831 $1.56 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $46,351 - $57,730	493 Added 16.53%	3,476 $391,000
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $8,953 - $10,487	100 Added 3.47%	2,983 $281,000
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $5,928 - $7,750	-63 Reduced 2.14%	2,883 $291,000
Q4 2022 Feb 15, 2023	BUY	$106.72 - $127.06 $108,534 - $129,220	1,017 Added 52.72%	2,946 $351,000
Q3 2022 Nov 16, 2022	BUY	$92.03 - $107.81 $24,387 - $28,569	265 Added 15.93%	1,929 $205,000
Q2 2022 Aug 23, 2022	SELL	$75.79 - $100.07 $12,429 - $16,411	-164 Reduced 8.97%	1,664 $162,000
Q2 2022 Aug 16, 2022	BUY	$75.79 - $100.07 $32,892 - $43,430	434 Added 31.13%	1,828 $178,000
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $7,607 - $9,955	-105 Reduced 7.0%	1,394 $131,000
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $18,478 - $24,643	232 Added 18.31%	1,499 $128,000
Q3 2021 Nov 16, 2021	BUY	$86.18 - $99.03 $2,671 - $3,069	31 Added 2.51%	1,267 $122,000
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $18,333 - $20,965	205 Added 19.88%	1,236 $120,000
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $90,284 - $123,101	1,031 New	1,031 $100,000
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $9,287 - $12,686	-107 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $7,416 - $9,793	107 New	107 $9,000
Q4 2018 Feb 13, 2019	SELL	$68.32 - $124.36 $10,521 - $19,151	-154 Closed	0 $0
Q3 2018 Nov 15, 2018	BUY	$98.88 - $125.85 $15,227 - $19,380	154 New	154 $19,000

Others Institutions Holding NBIX

# of Institutions

718

Shares Held

102M

Call Options Held

228K

Put Options Held

336K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.

Account

Captrust Financial Advisors Neurocrine Biosciences Inc Transaction History